Subjects Considered Likely to Respond to CB-03-10
1 clinical trials · Condition
◉ Watch Subjects Considered Likely to Respond to CB-03-10
| Record | Firm | Date |
|---|---|---|
| Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors (NCT03863145) | Cosmo Technologies Ltd | 2022-06-14 |
Track Subjects Considered Likely to Respond to CB-03-10 automatically
Every clearance here is in the API, with alerts when new ones post.